| Characteristic | Percentage increase |
|---|---|
| South Dakota | 586.2% |
| Iowa | 407.1% |
| North Dakota | 318.2% |
| Arkansas | 272.6% |
| Oregon | 240.4% |
| Wyoming | 238.3% |
| Kentucky | 232.8% |
| Minnesota | 227.6% |
| Indiana | 225.2% |
| North Carolina | 219.4% |
| Washington | 216.3% |
| Nebraska | 209.8% |
| Idaho | 204.3% |
| New Hampshire | 201.8% |
| West Virginia | 199% |
| New Mexico | 198.2% |
| Maine | 173.4% |
| Virginia | 170.4% |
| Colorado | 168.8% |
| Montana | 163.1% |
| Missouri | 162.7% |
| Ohio | 151.8% |
| South Carolina | 144% |
| Alaska | 134.3% |
| Wisconsin | 119.6% |
| Arizona | 118.3% |
| Vermont | 111.6% |
| Oklahoma | 110.9% |
| Maryland | 107.9% |
| U.S. total | 104.2% |
| New York | 103.6% |
| Pennsylvania | 101.5% |
| Massachusetts | 89.8% |
| Illinois | 85.7% |
| California | 80.5% |
| Kansas | 80.4% |
| Delaware | 78.7% |
| Tennessee | 76.6% |
| District Of Columbia | 72.6% |
| Michigan | 60.6% |
| Rhode Island | 57.7% |
| Nevada | 56.6% |
| Alabama | 55.3% |
| Utah | 55.2% |
| Connecticut | 53.5% |
| Texas | 40% |
| Georgia | 30.4% |
| Florida | 27.6% |
| New Jersey | 26.8% |
| Louisiana | 26% |
| Hawaii | 17.9% |
| Mississippi | -1% |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Sources
Release date
September 2022
More information
Region
United States
Survey time period
2012 to 2021
Supplementary notes
Data comes from IQVIA Xponent.
From the source: "IQVIA Xponent limited to retail pharmacy dispensed prescriptions; USC 78340 (drug dependency), which includes molecules buprenorphine (except where indicated for pain management in USC 02200), buprenorphine/naloxone, naltrexone."
Citation formats
